Insider Selling: Crescent Biopharma (NASDAQ:CBIO) CEO Sells $28,819.00 in Stock

Crescent Biopharma, Inc. (NASDAQ:CBIO) CEO Joshua Brumm sold 1,610 shares of the stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $17.90, for a total transaction of $28,819.00. Following the sale, the chief executive officer owned 279,602 shares in the company, valued at $5,004,875.80. The trade was a 0.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Crescent Biopharma Price Performance

NASDAQ:CBIO traded up $0.12 during mid-day trading on Friday, reaching $16.89. The stock had a trading volume of 3,123,507 shares, compared to its average volume of 294,314. The stock has a 50-day simple moving average of $17.12 and a two-hundred day simple moving average of $17.43. The stock has a market capitalization of $627.36 million, a PE ratio of -2.51 and a beta of 1.24. Crescent Biopharma, Inc. has a 12 month low of $8.72 and a 12 month high of $27.41.

Crescent Biopharma (NASDAQ:CBIO) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, hitting the consensus estimate of ($0.74). Equities analysts expect that Crescent Biopharma, Inc. will post -2.91 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on CBIO shares. TD Cowen raised Crescent Biopharma to a “strong-buy” rating in a research note on Monday, August 24th. Wedbush restated an “outperform” rating and issued a $27.00 price target on shares of Crescent Biopharma in a research note on Monday. HC Wainwright reaffirmed a “neutral” rating on shares of Crescent Biopharma in a report on Thursday, July 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Crescent Biopharma in a research report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $29.60.

Crescent Biopharma News Roundup

Here are the key news stories impacting Crescent Biopharma this week:

• Neutral Sentiment: CEO Joshua Brumm, COO Jonathan McNeill, CFO Richard Scalzo, and other insiders collectively sold 16,726 shares worth approximately $285,501 between September 16 and September 18. The sales reduced individual holdings by roughly 0.5% to 3.2%, but insiders continued to retain meaningful positions. SEC insider transaction filing
• Neutral Sentiment: All reported transactions were executed under pre-arranged Rule 10b5-1 trading plans and were described as sales to cover tax-withholding obligations tied to vested equity awards. That reduces the likelihood that the transactions represent a change in management’s outlook, although the aggregate selling may still weigh modestly on sentiment. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by senior executives—including the CEO and COO—could be viewed as a near-term supply or sentiment overhang. However, the relatively small percentage reductions and tax-related rationale make this a limited negative signal rather than a clear indication of weakening business prospects. SEC insider transaction filing

Institutional Investors Weigh In On Crescent Biopharma

Institutional investors have recently added to or reduced their stakes in the business. Opaleye Management Inc. increased its position in Crescent Biopharma by 0.5% in the 2nd quarter. Opaleye Management Inc. now owns 1,319,351 shares of the biopharmaceutical company’s stock valued at $23,748,000 after acquiring an additional 6,736 shares during the period. Squarepoint Ops LLC acquired a new position in shares of Crescent Biopharma during the second quarter worth $435,000. Wellington Management Group LLP bought a new stake in shares of Crescent Biopharma in the second quarter worth $263,000. Stonepine Capital Management LLC bought a new stake in shares of Crescent Biopharma in the second quarter worth $720,000. Finally, Bank of America Corp DE acquired a new stake in Crescent Biopharma in the second quarter valued at $465,000. 75.19% of the stock is owned by institutional investors.

Crescent Biopharma Company Profile

Crescent Biopharma, Inc (NASDAQ: CBIO) is a biopharmaceutical company focused on discovering and developing innovative therapies for the treatment of serious diseases. The company’s activities center on research, preclinical development and clinical evaluation of investigational drug candidates.

Crescent Biopharma does not appear to have commercially marketed products. Its pipeline consists of experimental therapies intended to address significant unmet medical needs, although detailed information about specific candidates, therapeutic areas and development stages may be limited in publicly available sources.

The company is headquartered in the United States and serves the biopharmaceutical market through its drug-development programs and potential future partnerships.